Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Targeted Pathway Inhibition in Patients With Pancreatic Cancer

Conditions: Locally Advanced Pancreatic Ductal Adenocarcinoma; Metastatic Pancreatic Ductal Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Ductal Adenocarcinoma
Interventions: Drug: Cobimetinib; Drug: Olaparib; Drug: Onvansertib; Drug: Azenosertib
Sponsors: OHSU Knight Cancer Institute; American Association for Cancer Research; Oregon Health and Science University; Genentech, Inc.; Cardiff Oncology
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 6, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments